Research Objectives

 
Stock Quotes for Research Objectives top ^
  • Industry: Software - Application
  • Sector: Technology
  • Stock Style: Small Core
Sign-up for ocl investment picks

 
News Articles for Research Objectives top ^
2014/10/28
CI Investments announces changes to the investment objectives of nine funds Canada NewsWire TSX Symbol: CIX TORONTO , Oct.
Sign-up for CI Investments announces changes to the investment objectives of nine funds investment picks
RGS, a business unit of Avnet, Inc .
Sign-up for RGS Scales Mountains of Big Data with New Object Storage Solution in the Americas investment picks
2014/11/20
By Dominic Chopping STOCKHOLM--Swedish truck maker Volvo AB (VOLV-B.SK) said Thursday that it has received a Statement of Objections from the European Commission, stating the Commission's preliminary view that Volvo and other companies in the truck industry may have breached EU antitrust rules.
Sign-up for Volvo Gets Statement of Objections in Commission's Antitrust Probe investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives.
Sign-up for Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies investment picks
Liquidity Services, Inc. (NASDAQ: LQDT): Business Realignment Actions Liquidity Services, a global solutions provider in the reverse supply chain with the leading marketplace for business surplus, today announced it has realigned its workforce in response to the new terms and scope of its Department of Defense (DoD) Surplus Contract, competitively bid in April 2014, and to adjust for the efficiencies realized in its commercial business through ongoing integration efforts to support the future vision and growth of the Company.
Sign-up for Liquidity Services Announces Business Realignment Actions and New Senior Leadership Appointments to Support Integration and Growth Objectives investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, administered as a single agent in patients with advanced squamous cell non-small cell lung cancer (NSCLC) who have progressed after at least two prior systemic treatments with 65% receiving three or more prior therapies (n=117). With approximately 11 months of minimum follow up, the objective response rate (ORR, the study’s primary endpoint) was 15% (95% CI = 8.7, 22.2) as assessed by an independent review committee (IRC) using RECIST 1.1 criteria and the median duration of response was not reached.
Sign-up for Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology investment picks
2014/10/21
MORRIS TOWNSHIP, N.J. , Oct.
Sign-up for Honeywell Responds To European Commission Statement Of Objections investment picks
2014/8/29
Regualtory News: The Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY), chaired by Marc de Garidel, met on 28 August 2014 to approve the financial statements for the first half 2014, published today.
Sign-up for Ipsen: 2014 Half-Year Results and 2014 Objectives investment picks
2014/9/24
Leiden, The Netherlands, Sept.
Sign-up for Prosensa publishes a sensitive, reproducible and objective methodology for dystrophin analysis in patients with Duchenne muscular dystrophy investment picks
Lilien Systems, a wholly-owned subsidiary of Sysorex Global Holdings Corp.
Sign-up for Lilien Systems Announces New Reseller Partner Agreements with Seagate and Basho for Object Storage Solutions investment picks
Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018 Guides to Improved Adjusted Operating Margin of 52-54 Percent by 2018 Reinitiating Share Repurchases With Plans for Approximately $2 Billion Through 2015 Plans to Increase Dividend 30 Percent Beginning 1Q 2015 Expects to Deliver Double-Digit Adjusted Earnings Per Share (EPS) Growth on Average Through 2018 $1.5 Billion in Annual Savings Planned by 2018 Preparing to Launch Four High-Potential Innovative Medicines in 2015 Expands Biosimilars Portfolio to Nine Programs, Total Portfolio Represents a $3 Billion Plus Opportunity Launching Next-Generation Biomanufacturing Technologies in 2017 Provides Preliminary 2015 Guidance of Revenues of $20.8-$21.3 Billion and Adjusted EPS of $9.05-$9.40 NEW YORK , Oct.
Sign-up for Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Objectives
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Note  |  Next: Research Offers